About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 283985, 12 pages
http://dx.doi.org/10.1155/2013/283985
Research Article

Analysis of Activated Platelet-Derived Growth Factor β Receptor and Ras-MAP Kinase Pathway in Equine Sarcoid Fibroblasts

1Department of Veterinary Medicine and Animal Production, University of Naples Federico II, Via Veterinaria, 180137 Napoli, Italy
2MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Bearsden Road, Glasgow G61 1QH, UK
3University College London, Internal Medicine, Division of Medicine, Faculty of Medical Sciences, Gower Street, London WC1E 6BT, UK

Received 14 February 2013; Revised 3 June 2013; Accepted 18 June 2013

Academic Editor: Marcelo Palma Sircili

Copyright © 2013 Gennaro Altamura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Borzacchiello and A. Corteggio, “Equine sarcoid: state of the art,” Ippologia, vol. 20, no. 4, pp. 7–14, 2009. View at Scopus
  2. A. Martens, A. De Moor, J. Demeulemeester, and R. Ducatelle, “Histopathological characteristics of five clinical types of equine sarcoid,” Research in Veterinary Science, vol. 69, no. 3, pp. 295–300, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. D. W. Scott and W. H. Miller, “Equine dermatology,” Journal of Equine Veterinary Science, vol. 23, no. 2, pp. 65–67, 2003.
  4. W. D. Lancaster, G. H. Theilen, and C. Olson, “Hybridization of bovine papilloma virus type 1 and type 2 DNA to DNA from virus-induced hamster tumors and naturally occurring equine tumors,” Intervirology, vol. 11, no. 4, pp. 227–233, 1979. View at Scopus
  5. N. T. Gorman, “Equine sarcoid—time for optimism,” Equine Veterinary Journal, vol. 17, no. 6, pp. 412–414, 1985. View at Scopus
  6. L. Nasir and M. S. Campo, “Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids,” Veterinary Dermatology, vol. 19, no. 5, pp. 243–254, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Borzacchiello and F. Roperto, “Bovine papillomaviruses, papillomas and cancer in cattle,” Veterinary Research, vol. 39, no. 5, article 45, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Nasir and S. W. J. Reid, “Bovine papillomaviral gene expression in equine sarcoid tumours,” Virus Research, vol. 61, no. 2, pp. 171–175, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. E. A. Carr, A. P. Théon, B. R. Madewell, M. E. Hitchcock, R. Schlegel, and J. T. Schiller, “Expression of a transforming gene (E5) of bovine papillomavirus in sarcoids obtained from horses,” American Journal of Veterinary Research, vol. 62, no. 8, pp. 1212–1217, 2001. View at Scopus
  10. G. Chambers, V. A. Ellsmore, P. M. O'Brien et al., “Sequence variants of bovine papillomavirus E5 detected in equine sarcoids,” Virus Research, vol. 96, no. 1-2, pp. 141–145, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Borzacchiello, V. Russo, L. Della Salda, S. Roperto, and F. Roperto, “Expression of platelet-derived growth factor-beta receptor and bovine papillomavirus E5 and E7 oncoproteins in equine sarcoid,” Journal of Comparative Pathology, vol. 139, no. 4, pp. 231–237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Corteggio, G. Altamura, F. Roperto, and G. Borzacchiello, “Bovine papillomavirus E5 and E7 oncoproteins in naturally occurring tumors: are two better than one?” Infectious Agents and Cancer, vol. 8, article 1, 2013.
  13. A. Venuti, F. Paolini, L. Nasir et al., “Papillomavirus E5: the smallest oncoprotein with many functions,” Molecular Cancer, vol. 10, article 140, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. W. D. Pennie, G. J. Grindlay, M. Cairney, and M. S. Campo, “Analysis of the transforming functions of bovine papillomavirus type 4,” Virology, vol. 193, no. 2, pp. 614–620, 1993. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Borzacchiello, V. Russo, F. Gentile et al., “Bovine papillomavirus E5 oncoprotein binds to the activated form of the platelet-derived growth factor β receptor in naturally occurring bovine urinary bladder tumours,” Oncogene, vol. 25, no. 8, pp. 1251–1260, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. D. DiMaio and D. Mattoon, “Mechanisms of cell transformation by papillomavirus E5 proteins,” Oncogene, vol. 20, no. 54, pp. 7866–7873, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. D. J. Goldstein, W. Li, L.-M. Wang et al., “The bovine papillomavirus type 1 E5 transforming protein specifically binds and activates the β-type receptor for the platelet-derived growth factor but not other related tyrosine kinase-containing receptors to induce cellular transformation,” Journal of Virology, vol. 68, no. 7, pp. 4432–4441, 1994. View at Scopus
  18. L. Petti, L. A. Nilson, and D. DiMaio, “Activation of the platelet-derived growth factor receptor by the bovine papillomavirus E5 transforming protein,” The EMBO Journal, vol. 10, no. 4, pp. 845–855, 1991. View at Scopus
  19. V. M. Nappi and L. M. Petti, “Multiple transmembrane amino acid requirements suggest a highly specific interaction between the bovine papillomavirus E5 oncoprotein and the platelet-derived growth factor beta receptor,” Journal of Virology, vol. 76, no. 16, pp. 7976–7986, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. C.-C. Lai, C. Henningson, and D. Dimaio, “Bovine papillomavirus E5 protein induces oligomerization and trans-phosphorylation of the platelet-derived growth factor β receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 26, pp. 15241–15246, 1998. View at Scopus
  21. O. Klein, D. Kegler-Ebo, J. Su, S. Smith, and D. DiMaio, “The bovine papillomavirus E5 protein requires a juxtamembrane negative charge for activation of the platelet-derived growth factor β receptor and transformation of C127 cells,” Journal of Virology, vol. 73, no. 4, pp. 3264–3272, 1999. View at Scopus
  22. L. M. Petti, E. C. Ricciardi, H. J. Page, and K. A. Porter, “Transforming signals resulting from sustained activation of the PDGFβ receptor in mortal human fibroblasts,” Journal of Cell Science, vol. 121, no. 8, pp. 1172–1182, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Roperto, G. Borzacchiello, I. Esposito et al., “Productive infection of bovine papillomavirus type 2 in the placenta of pregnant cows affected with urinary bladder tumors,” PLoS ONE, vol. 7, no. 3, Article ID e33569, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Borzacchiello, S. Mogavero, G. De Vita, S. Roperto, L. Della Salda, and F. Roperto, “Activated platelet-derived growth factor β receptor expression, PI3K-AKT pathway molecular analysis, and transforming signals in equine sarcoids,” Veterinary Pathology, vol. 46, no. 4, pp. 589–597, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Corteggio, O. Di Geronimo, S. Roperto, F. Roperto, and G. Borzacchiello, “Activated platelet-derived growth factor β receptor and Ras-mitogen-activated protein kinase pathway in natural bovine urinary bladder carcinomas,” Veterinary Journal, vol. 191, no. 3, pp. 393–395, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Carnero, “The PKB/AKT pathway in cancer,” Current Pharmaceutical Design, vol. 16, no. 1, pp. 34–44, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. S. J. Moeller, E. D. Head, and R. J. Sheaff, “p27Kip1 inhibition of GRB2-SOS formation can regulate Ras activation,” Molecular and Cellular Biology, vol. 23, no. 11, pp. 3735–3752, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Dance, A. Montagner, J.-P. Salles, A. Yart, and P. Raynal, “The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway,” Cellular Signalling, vol. 20, no. 3, pp. 453–459, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. N. A. Lokker, C. M. Sullivan, S. J. Hollenbach, M. A. Israel, and N. A. Giese, “Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors,” Cancer Research, vol. 62, no. 13, pp. 3729–3735, 2002. View at Scopus
  30. B. J. Druker, S. Tamura, E. Buchdunger et al., “Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells,” Nature Medicine, vol. 2, no. 5, pp. 561–566, 1996. View at Scopus
  31. E. Buchdunger, J. Zimmermann, H. Mett et al., “Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2- phenylaminopyrimidine derivative,” Cancer Research, vol. 56, no. 1, pp. 100–104, 1996. View at Scopus
  32. E. Buchdunger, C. L. Cioffi, N. Law et al., “Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors,” The Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 1, pp. 139–145, 2000. View at Scopus
  33. T. Kilic, J. A. Alberta, P. R. Zdunek et al., “Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class,” Cancer Research, vol. 60, no. 18, pp. 5143–5150, 2000. View at Scopus
  34. B. P. Rubin, S. M. Schuetze, J. F. Eary et al., “Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans,” Journal of Clinical Oncology, vol. 20, no. 17, pp. 3586–3591, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Sjöblom, A. Shimizu, K. P. O'Brien et al., “Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis,” Cancer Research, vol. 61, no. 15, pp. 5778–5783, 2001. View at Scopus
  36. E. C. McGary, K. Weber, L. Mills et al., “Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571,” Clinical Cancer Research, vol. 8, no. 11, pp. 3584–3591, 2002. View at Scopus
  37. R. E. Gilbert, D. J. Kelly, T. McKay et al., “PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis,” Kidney International, vol. 59, no. 4, pp. 1324–1332, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. B. J. Druker and N. B. Lydon, “Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia,” The Journal of Clinical Investigation, vol. 105, no. 1, pp. 3–7, 2000. View at Scopus
  39. M. J. Mauro, M. O'Dwyer, M. C. Heinrich, and B. J. Druker, “STI571: a paradigm of new agents for cancer therapeutics,” Journal of Clinical Oncology, vol. 20, no. 1, pp. 325–334, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. G. W. Krystal, S. Honsawek, J. Litz, and E. Buchdunger, “The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth,” Clinical Cancer Research, vol. 6, no. 8, pp. 3319–3326, 2000. View at Scopus
  41. A. T. van Oosterom, I. Judson, J. Verweij et al., “Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study,” The Lancet, vol. 358, no. 9291, pp. 1421–1423, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. A. T. van Oosterom, I. R. Judson, J. Verweij et al., “Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group,” European Journal of Cancer, vol. 38, supplement 5, pp. S83–S87, 2002. View at Scopus
  43. M. Isotani, N. Ishida, M. Tominaga et al., “Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs,” Journal of Veterinary Internal Medicine, vol. 22, no. 4, pp. 985–988, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Marconato, G. Bettini, C. Giacoboni et al., “Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement,” Journal of Veterinary Internal Medicine, vol. 22, no. 4, pp. 1001–1007, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. O. Yamada, M. Kobayashi, O. Sugisaki et al., “Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation,” Veterinary Immunology and Immunopathology, vol. 142, no. 1-2, pp. 101–106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. J. L. Lachowicz, G. S. Post, and E. Brodsky, “A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats,” Journal of Veterinary Internal Medicine, vol. 19, no. 6, pp. 860–864, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Katayama, M. K. Huelsmeyer, A. K. Marr, I. D. Kurzman, D. H. Thamm, and D. M. Vail, “Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma,” Cancer Chemotherapy and Pharmacology, vol. 54, no. 1, pp. 25–33, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. Z. Q. Yuan, E. A. Gault, P. Gobeil, C. Nixon, M. S. Campo, and L. Nasir, “Establishment and characterization of equine fibroblast cell lines transformed in vivo and in vitro by BPV-1: Model systems for equine sarcoids,” Virology, vol. 373, no. 2, pp. 352–361, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. Z. Yuan, E. A. Gault, M. Saveria Campo, and L. Nasir, “Different contribution of bovine papillomavirus type 1 oncoproteins to the transformation of equine fibroblasts,” The Journal of General Virology, vol. 92, no. 4, pp. 773–783, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. U. K. Laemmli, “Cleavage of structural proteins during the assembly of the head of bacteriophage T4,” Nature, vol. 227, no. 5259, pp. 680–685, 1970. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Borzacchiello, V. Russo, C. Spoleto et al., “Bovine papillomavirus type-2 DNA and expression of E5 and E7 oncoproteins in vascular tumours of the urinary bladder in cattle,” Cancer Letters, vol. 250, no. 1, pp. 82–91, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. M. A. Silva, G. Altamura, A. Corteggio, et al., “Expression of connexin 26 and bovine papillomavirus E5 in cutaneous fibropapillomas of cattle,” The Veterinary Journal, vol. 195, no. 3, pp. 337–343, 2013.
  53. M. S. Campo, R. E. McCaffery, I. Doherty, I. M. Kennedy, and W. F. H. Jarrett, “The Harvey ras 1 gene is activated in papillomavirus-associated carcinomas of the upper alimentary canal in cattle,” Oncogene, vol. 5, no. 3, pp. 303–308, 1990. View at Scopus
  54. J. Ghai, R. S. Ostrow, J. Tolar et al., “The E5 gene product of rhesus papillomavirus is an activator of endogenous Ras and phosphatidylinositol-3′-kinase in NIH 3T3 cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 23, pp. 12879–12884, 1996. View at Scopus
  55. M. Zago, M. S. Campo, and V. O'Brien, “Cyclin A expression and growth in suspension can be uncoupled from p27 deregulation and extracellular signal-regulated kinase activity in cells transformed by bovine papillomavirus type 4 E5,” The Journal of General Virology, vol. 85, no. 12, pp. 3585–3595, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Corteggio, O. Di Geronimo, S. Roperto, F. Roperto, and G. Borzacchiello, “Bovine papillomavirus E7 oncoprotein binds to p600 in naturally occurring equine sarcoids,” The Journal of General Virology, vol. 92, no. 2, pp. 378–382, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. S. H. Song, J. K. Lee, J. Y. Hur, I. Kim, H. S. Saw, and Y. K. Park, “The expression of epidermal growth factor receptor, vascular endothelial growth factor, matrix metalloproteinase-2, and cyclooxygenase-2 in relation to human papilloma viral load and persistence of human papillomavirus after conization with negative margins,” International Journal of Gynecological Cancer, vol. 16, no. 6, pp. 2009–2017, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. T. R. Golub, G. F. Barker, M. Lovett, and D. Gary Gilliland, “Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation,” Cell, vol. 77, no. 2, pp. 307–316, 1994. View at Publisher · View at Google Scholar · View at Scopus
  59. M. C. Heinrich, C. L. Corless, A. Duensing et al., “PDGFRA activating mutations in gastrointestinal stromal tumors,” Science, vol. 299, no. 5607, pp. 708–710, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Hirota, A. Ohashi, T. Nishida et al., “Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors,” Gastroenterology, vol. 125, no. 3, pp. 660–667, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Hirota, “Gain-of-function mutation of c-kit gene and molecular target therapy in GISTs,” Japanese Journal of Gastroenterology, vol. 100, no. 1, pp. 13–20, 2003. View at Scopus
  62. N. Sirvent, G. Maire, and F. Pedeutour, “Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment,” Genes Chromosomes and Cancer, vol. 37, no. 1, pp. 1–19, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Giantin, M. Vascellari, E. M. Morello et al., “c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis,” Journal of Veterinary Diagnostic Investigation, vol. 24, no. 1, pp. 116–126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. I. Matsumura, M. Mizuki, and Y. Kanakura, “Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies,” Cancer Science, vol. 29, no. 3, pp. 479–485, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Burkhardt, M. Willingham, C. Gay, K.-T. Jeang, and R. Schlegel, “The E5 oncoprotein of bovine papillomavirus is oriented asymmetrically in Golgi and plasma membranes,” Virology, vol. 170, no. 1, pp. 334–339, 1989. View at Scopus
  66. K. Talbert-Slagle and D. DiMaio, “The bovine papillomavirus E5 protein and the PDGF β receptor: it takes two to tango,” Virology, vol. 384, no. 2, pp. 345–351, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. C. A. London, “Tyrosine kinase inhibitors in veterinary medicine,” Topics in Companion Animal Medicine, vol. 24, no. 3, pp. 106–112, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Nilsson, J. Thyberg, C. H. Heldin, B. Westermark, and A. Wasteson, “Surface binding and internalization of platelet-derived growth factor in human fibroblasts,” Proceedings of the National Academy of Sciences of the United States of America, vol. 80, no. 181, pp. 5592–5596, 1983. View at Scopus
  69. J. L. Goldstein, M. S. Brown, R. G. Anderson, D. W. Russell, and W. J. Schneider, “Receptor-mediated endocytosis: concepts emerging from the LDL receptor system,” Annual Review of Cell Biology, vol. 1, pp. 1–39, 1985. View at Scopus